<i>Plasmodium vivax</i>Malaria–associated Acute Kidney Injury, India, 2010–2011

Kute, Vivek B.; Trivedi, Hargovind L; Vanikar, Aruna V; Shah, Pankaj; Gumber, Manoj R.; Patel, Himanshu V.; Goswami, Jitendra; Kanodia, Kamal V

doi:10.3201/eid1805.111442

Cited by 49 publications

(44 citation statements)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the P.falciparum malaria, there are reports showing complications in P.vivax patients with organ failure [53]–[57]. This indicates that P.vivax should also show cytoadherence to endothelial cells of these internal organs to give rise to such complications.…”

Section: Discussionmentioning

confidence: 83%

Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients’ Antibodies

Tyagi

Sharma

2012

PLoS ONE

View full text Add to dashboard Cite

Plasmodium vivax is a very common but non-cultivable malaria parasite affecting large human population in tropical world. To develop therapeutic reagents for this malaria, the parasite molecules involved in host-parasite interaction need to be investigated as they form effective vaccine or drug targets. We have investigated here the erythrocyte binding activity of a group of 15 different Plasmodium vivax tryptophan rich antigens (PvTRAgs). Only six of them, named PvTRAg, PvTRAg38, PvTRAg33.5, PvTRAg35.2 PvTRAg69.4 and PvATRAg74, showed binding to host erythrocytes. That the PvTRAgs binding to host erythrocytes was specific was evident from the competitive inhibition and saturation kinetics results. The erythrocyte receptors for these six PvTRAgs were resistant to trypsin and neuraminidase. These receptors were also chymotrypsin resistant except the receptors for PvTRAg38 and PvATRAg74 which were partially sensitive to this enzyme. The cross-competition studies showed that the chymotrypsin resistant RBC receptor for each of these two proteins was different. Altogether, there seems to be three RBC receptors for these six PvTRAgs and each PvTRAg has two RBC receptors. Both RBC receptors for PvTRAg, PvTRAg69.4, PvTRAg33.5, and PvTRAg35.2 were common to all these four proteins. These four PvTRAgs also shared one of their RBC receptors with PvTRAg38 as well as with PvATRAg74. The erythrocyte binding activity of these six PvTRAgs was inhibited by the respective rabbit polyclonal antibodies as well as by the natural antibodies produced by the P. vivax exposed individuals. It is concluded that only selective few PvTRAgs show erythrocyte binding activity involving different receptor molecules which can be blocked by the natural antibodies. Further studies on these receptor and ligands may lead to the development of therapeutic reagents for P. vivax malaria.

show abstract

Section: Discussionmentioning

confidence: 83%

Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients’ Antibodies

Tyagi

Sharma

2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Reported severe manifestations of Pv include cerebral malaria, liver dysfunction, acute kidney injury, severe anemia, acute respiratory distress syndrome, shock, abnormal bleeding, and multiple organ failure. [11] Profound thrombocytopenia with platelet count as low as 5000/μl has been reported in the Indian literature in a 43-year-old female patient with Pv malaria. [12] This must be considered in the context that very low platelet counts can be transient in the course of malaria illness and may not necessarily have prognostic implications or merit platelet infusions.…”

Section: Resultsmentioning

confidence: 94%

Thrombocytopenia in malaria and its correlation with different types of malaria

Gill

Makkar

Bhat

et al. 2013

Ann Trop Med Public Health

View full text Add to dashboard Cite

Aim of the Study: Malaria is a major health problem in the tropics with increased morbidity and mortality. Thrombocytopenia is a common finding in malaria. Although a reliable diagnostic marker, prognostic implications could vary in the two types of malaria. This study was undertaken to assess the presence and severity of thrombocytopenia in malaria patients. Design: A total of 120 patients were included in the study and identified positive for malaria parasites on peripheral smear examination with conventional microscopy. Platelet count was done on a fully automated, quantitative, hematology analyzer. Results: Thrombocytopenia was noted in 63.33% cases. The mean platelet count in Plasmodium vivax (Pv) malaria was 1,27,652/μl (SD 78,269) with a range of 8000-3,50,000/μl, as against Plasmodium falciparum (Pf) malaria where the mean platelet count was 78,500/μl (SD 51,485) with a range of 9000-1,90,000/μl. Platelet count < 50,000/μl was noted in only 17.4% cases of Pv malaria as against 33.3% cases of Pf malaria. Conclusion: Although absence of thrombocytopenia is uncommon in malaria, its presence is not a distinguishing feature between the two types of malaria. Our study stresses the importance of thrombocytopenia as an indicator of acute malaria.

show abstract

“…There seems to be no clear correlation between the burden of parasitemia and the severity of illness, at least on the scales of parasitemia typically applied to P. falciparum, e.g., Ͼ200,000/l comes with a significant risk of a poor outcome. Table 5 lists evidence from case series (110)(111)(112)(113)(114)(115)(116)(117)(118)(119). These represent cases selected by the authors from their clinical experiences.…”

Section: Current Evidence Case Reportsmentioning

confidence: 99%

Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria

2013

View full text Add to dashboard Cite

SUMMARYVivax malaria threatens patients despite relatively low-grade parasitemias in peripheral blood. The tenet of death as a rare outcome, derived from antiquated and flawed clinical classifications, disregarded key clinical evidence, including (i) high rates of mortality in neurosyphilis patients treated with vivax malaria; (ii) significant mortality from zones of endemicity; and (iii) the physiological threat inherent in repeated, very severe paroxysms in any patient, healthy or otherwise. The very well-documented course of this infection, with the exception of parasitemia, carries all of the attributes of “perniciousness” historically linked to falciparum malaria, including severe disease and fatal outcomes. A systematic analysis of the parasite biomass in severely ill patients that includes blood, marrow, and spleen may ultimately explain this historic misunderstanding. Regardless of how this parasite is pernicious, recent data demonstrate that the infection comes with a significant burden of morbidity and associated mortality. The extraordinary burden of malaria is not heavily weighted upon any single continent by a single species of parasite—it is a complex problem for the entire endemic world, and both species are of fundamental importance. Humanity must rally substantial resources, intellect, and energy to counter this daunting but profound threat.

show abstract

Plasmodium vivaxMalaria–associated Acute Kidney Injury, India, 2010–2011

Cited by 49 publications

References 12 publications

Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients’ Antibodies

Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients’ Antibodies

Thrombocytopenia in malaria and its correlation with different types of malaria

Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria

Contact Info

Product

Resources

About